难以下咽的药丸：英国国家医疗服务体系（NHS）如何限制高价药品的获取。 - Suppr

Suppr

超能文献

A pill too hard to swallow: how the NHS is limiting access to high priced drugs.

作者信息

Gornall Jonathan, Hoey Amanda, Ozieranski Piotr

机构信息

Suffolk, UK.

Department of Social and Policy Sciences, University of Bath, Bath, UK.

出版信息

BMJ. 2016 Jul 27;354:i4117. doi: 10.1136/bmj.i4117.

DOI:10.1136/bmj.i4117

PMID:27469086

Abstract

摘要

相似文献

A pill too hard to swallow: how the NHS is limiting access to high priced drugs.

BMJ. 2016 Jul 27;354:i4117. doi: 10.1136/bmj.i4117.

High cost of new drugs.

BMJ. 2016 Jul 27;354:i4136. doi: 10.1136/bmj.i4136.

Determining the value of drugs--the evolving British experience.

N Engl J Med. 2011 Apr 7;364(14):1289-91. doi: 10.1056/NEJMp1101047.

Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.

N Engl J Med. 2019 Feb 14;380(7):605-607. doi: 10.1056/NEJMp1812959.

Network. BME service-user led projects.

Ment Health Today. 2012 Jan-Feb:29.

Compulsory licences for direct acting antiviral drugs for hepatitis C.

BMJ. 2016 Oct 5;355:i5314. doi: 10.1136/bmj.i5314.

The enigma of value: in search of affordable and accessible health care.

Eur J Health Econ. 2017 Jul;18(6):667-670. doi: 10.1007/s10198-016-0857-3. Epub 2016 Dec 2.

New NICE criteria for drug access.

Lancet Oncol. 2017 May;18(5):576. doi: 10.1016/S1470-2045(17)30235-8. Epub 2017 Mar 23.

Eliminating innovation: how price controls limit access.

J Leg Med. 2011 Jan;32(1):115-28. doi: 10.1080/01947648.2011.550833.

Overcoming injustice: A roadmap to improve access to hepatitis C virus therapy for our medicaid patients.

Hepatology. 2017 May;65(5):1735-1740. doi: 10.1002/hep.29095. Epub 2017 Mar 31.

引用本文的文献

The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.

Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.

An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.

BMC Med Ethics. 2024 Mar 6;25(1):28. doi: 10.1186/s12910-024-01016-0.

A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.

PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021.

The Lived Experience of Inequalities in the Provision of Treatment for Hepatitis C.

Front Sociol. 2021 Jun 1;6:649838. doi: 10.3389/fsoc.2021.649838. eCollection 2021.

Affordability and Non-Perfectionism in Moral Action.

Ethical Theory Moral Pract. 2019;22(4):973-991. doi: 10.1007/s10677-019-10028-4. Epub 2019 Sep 14.

Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA.

Epidemiol Infect. 2018 Oct;146(14):1845-1853. doi: 10.1017/S0950268818002042. Epub 2018 Aug 2.

Priority Setting: Right Answer to a Far Too Narrow Question? Comment on "Global Developments in Priority Setting in Health".

Int J Health Policy Manag. 2018 Jan 1;7(1):86-88. doi: 10.15171/ijhpm.2017.66.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

A pill too hard to swallow: how the NHS is limiting access to high priced drugs.

BMJ. 2016 Jul 27;354:i4117. doi: 10.1136/bmj.i4117.

High cost of new drugs.

BMJ. 2016 Jul 27;354:i4136. doi: 10.1136/bmj.i4136.

Determining the value of drugs--the evolving British experience.

N Engl J Med. 2011 Apr 7;364(14):1289-91. doi: 10.1056/NEJMp1101047.

Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.

N Engl J Med. 2019 Feb 14;380(7):605-607. doi: 10.1056/NEJMp1812959.

Network. BME service-user led projects.

Ment Health Today. 2012 Jan-Feb:29.

Compulsory licences for direct acting antiviral drugs for hepatitis C.

BMJ. 2016 Oct 5;355:i5314. doi: 10.1136/bmj.i5314.

The enigma of value: in search of affordable and accessible health care.

Eur J Health Econ. 2017 Jul;18(6):667-670. doi: 10.1007/s10198-016-0857-3. Epub 2016 Dec 2.

New NICE criteria for drug access.

Lancet Oncol. 2017 May;18(5):576. doi: 10.1016/S1470-2045(17)30235-8. Epub 2017 Mar 23.

Eliminating innovation: how price controls limit access.

J Leg Med. 2011 Jan;32(1):115-28. doi: 10.1080/01947648.2011.550833.

Overcoming injustice: A roadmap to improve access to hepatitis C virus therapy for our medicaid patients.

Hepatology. 2017 May;65(5):1735-1740. doi: 10.1002/hep.29095. Epub 2017 Mar 31.

引用本文的文献

The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.

Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.

An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.

BMC Med Ethics. 2024 Mar 6;25(1):28. doi: 10.1186/s12910-024-01016-0.

A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.

PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021.

The Lived Experience of Inequalities in the Provision of Treatment for Hepatitis C.

Front Sociol. 2021 Jun 1;6:649838. doi: 10.3389/fsoc.2021.649838. eCollection 2021.

Affordability and Non-Perfectionism in Moral Action.

Ethical Theory Moral Pract. 2019;22(4):973-991. doi: 10.1007/s10677-019-10028-4. Epub 2019 Sep 14.

Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA.

Epidemiol Infect. 2018 Oct;146(14):1845-1853. doi: 10.1017/S0950268818002042. Epub 2018 Aug 2.

Priority Setting: Right Answer to a Far Too Narrow Question? Comment on "Global Developments in Priority Setting in Health".

Int J Health Policy Manag. 2018 Jan 1;7(1):86-88. doi: 10.15171/ijhpm.2017.66.